Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

research and development ("R&D") programs and selling, general and administrative ("SG&A") activities to support recent growth were more than offset by higher revenues compared to 2009. On a US GAAP basis, operating income increased by $64 million, or 70%, to $156 million (2009: $92 million). US GAAP operating income in Q3 2010 also included an up-front payment of $45 million made to Acceleron Pharma Inc. ("Acceleron") in relation to the collaboration for activin receptor type IIB ("ActRIIB") molecules and impairment charges of $43 million following the decision to divest DAYTRANA(R) to Noven Pharmaceuticals Inc. ("Noven"). - Cash generation, which is a Non GAAP measure, increased by $51 million to $271 million (2009: $220 million). Higher cash receipts from product sales and royalties were partially offset by higher cash payments on the increased investment in R&D and SG&A, and the timing of sales deduction payments in 2010. - Net debt at September 30, 2010 was $309 million (December 31, 2009: $615 million), a reduction of $306 million in the year to date. Strong cash generation of $959 million in the nine months to September 30, 2010 has reduced net debt as well as funded the acquisition of and construction at Lexington Technology Park, cash tax payments and the upfront payment made to Acceleron. Excluding restricted cash of $584 million held to pay for the acquisition of Movetis NV ("Movetis") in the fourth quarter, net debt at September 30, 2010 was $893 million.

2010 OUTLOOK

Following a stronger than expected third quarter, we have increased our expectations for the full year 2010. We now expect to see Non GAAP earnings per ADS of up to $4.20. This increase includes the financial effect of the Movetis acquisition and the disposal of DAYTRANA on October 1, 2010; it also includes the cumulative impact of US Healthcare Reform, mandated European price cuts and adverse foreign exchange rates.

The strong growth of our core p
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market ... Administration (FDA) for the use of Medtronic,s SynchroMed ... a newly developed catheter) for use with United ... to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
...  Grifols, S.A. (NASDAQ: GRFS ) ... based in Barcelona, Spain today announced that on ... Talecris Biotherapeutics Holdings Corp. ("Talecris").  In partial consideration ... shares that trade in the U.S. as Grifols ...
... Masimo (NASDAQ: MASI ) today announced that its ... 31st Annual Growth Stock Conference at the Four Seasons Hotel in ... live audiocast of the presentation will be available on the Masimo ... be available following the live presentation. About ...
... for creating single-crystal arrays of the material graphene, an ... silicon in high-performance computers and electronics. The work by ... cover of the June issue of Nature Materials ... was first fabricated in 2004. Single-crystal arrays of the ...
Cached Biology Technology:Grifols Announces the Completion of its Acquisition of Talecris and the Listing of its ADSs on NASDAQ 2Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference 2University of Houston develops method for creating single-crystal arrays of graphene 2
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... b3c newswire / - Cambridge Healthtech Institute’s Fifth ... 27-29, 2009 at the Loews Philadelphia Hotel, Philadelphia, ... is April 10, 2009. , The signature event ... World Congress 2009 ( www.biomarkerworldcongress.com ) is dedicated ...
... MIT engineers and colleagues have observed the initiation of a ... animals in this case, fish. The work, conducted ... conservation of marine ecosystems that vast oceanic fish shoals inhabit," ... Science . It also confirms theories about the behavior ...
... fast bite spelled doom for bony fishes during the last ... study to be published March 31, 2009, in the ... Today, those same features characterize large predatory bony fishes, such ... at risk of extinction themselves, said Matt Friedman, author of ...
Cached Biology News:CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 2CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 3CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 4CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda 5Team IDs genesis of mass migrations 2Team IDs genesis of mass migrations 3Study unravels why certain fishes went extinct 65 million years ago 2Study unravels why certain fishes went extinct 65 million years ago 3
... adds two new Stem Cell Antibody Panels ... products. The Human Embryonic Stem Cell Marker ... antibodies against: alkaline phosphatase, Nanog, Oct-3/4, SSEA-1 ... Marker Antibody Panel Plus (Catalog # SC009) ...
... Printing Surface (3 glass slides coated with 100 /500/1000 ... wafer coated with 1000 Angstroms of Gold over TI ... (3 PDMS micropatterned stamps with series of 100 / ... or 200 um x 10 mm lines, 3 PDMS ...
...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Biology Products: